|
Significant Agreements and Contracts - Additional Information (Details) (USD $)
|
3 Months Ended |
1 Months Ended |
6 Months Ended |
0 Months Ended |
1 Months Ended |
|
Mar. 31, 2015
|
Mar. 31, 2014
|
Jul. 31, 2012
|
Jul. 31, 2010
|
Jun. 30, 2012
|
Aug. 31, 2014
|
May 31, 2013
|
Mar. 31, 2015
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Contract research |
$ 2,076,580 |
$ 2,983,830 |
|
|
|
|
|
|
| Optimer Pharmaceuticals Inc | Collaborative Arrangement |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Common shares issued to Optimer in exchange for license |
125,646 |
|
|
|
|
|
|
|
| Fair value of common shares issued to Optimer |
190,418 |
|
|
|
|
|
|
|
| Milestone payment paid to Optimer |
|
|
1,000,000 |
500,000 |
|
|
|
|
| Aggregate amount of milestone payment |
27,500,000 |
|
|
|
|
|
|
|
| Number of products required to be developed through FDA approval |
4 |
|
|
|
|
|
|
|
| Royalty payment based on annual net sales description |
The Company will also pay tiered mid-single-digit royalties based on the amount of annual net sales of licensed products outside the Association of Southeast Asian Nations (“ASEAN”) countries, which royalties are subject to reduction in the event additional licenses are obtained from third parties in order to practice the Company’s rights under the Optimer Agreement and/or the Company is required to grant a compulsory license to a third party. |
|
|
|
|
|
|
|
| The Scripps Research Institute |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Royalty payment based on annual net sales description |
Under the terms of the agreement, the Company must pay TSRI low single-digit percentage royalties on the net sales of the products covered by the TSRI patents for the life of the TSRI patents, a low single-digit percentage of non-royalty sublicensing revenue received with respect to countries in the nonexclusive territory and a mid-single-digit percentage of sublicensing revenue received with respect to countries in the exclusive territory, with the sublicensing revenue royalty in the exclusive territory and the sales royalties subject to certain reductions under certain circumstances. |
|
|
|
|
|
|
|
| Non refundable license issue fee |
|
|
|
|
350,000 |
|
|
|
| Eligible milestone payment |
1,100,000 |
|
|
|
|
|
|
|
| Sublicense fees paid |
200,000 |
|
|
|
|
|
|
|
| The Scripps Research Institute | First Three Years |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Annual maintenance fees |
50,000 |
|
|
|
|
|
|
|
| The Scripps Research Institute | Fourth Through Six Years |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Annual maintenance fees |
85,000 |
|
|
|
|
|
|
|
| Biomedical Advanced Research and Development Authority |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Value of cost plus fixed fee development contract with base performance segment |
17,700,000 |
|
|
|
|
|
|
|
| Number of option work segments |
4 |
|
|
|
|
|
|
|
| Cumulative value of cost plus fixed fee development contract with base performance segment of four option work segments |
58,000,000 |
|
|
|
|
|
|
|
| Number of options under cost plus fixed fee arrangements |
3 |
|
|
|
|
|
|
|
| Number of options under cost sharing arrangement |
1 |
|
|
|
|
|
|
|
| Aggregate milestone payments receivable under license agreement |
May 31, 2013 |
|
|
|
|
|
|
|
| Estimated period of performance for the base performance segment ending date |
Nov. 30, 2015 |
|
|
|
|
|
|
|
| Extended estimated period of performance for the base performance segment |
May 31, 2018 |
|
|
|
|
|
|
|
| Contract research |
15,200,000 |
|
|
|
|
|
|
|
| Biomedical Advanced Research and Development Authority | Second Option Work |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Value of cost plus fixed fee development contract with base performance segment |
16,000,000 |
|
|
|
|
|
|
|
| Aggregate milestone payments receivable under license agreement |
Nov. 30, 2014 |
|
|
|
|
|
|
|
| Estimated period of performance for the base performance segment ending date |
Nov. 30, 2016 |
|
|
|
|
|
|
|
| Toyama Chemical |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Contract research |
3,200,000 |
|
|
|
|
|
|
|
| Deferred revenue |
11,400,000 |
|
|
|
|
|
10,000,000 |
11,400,000 |
| Aggregate milestone payments |
|
|
|
|
|
|
60,000,000 |
|
| Milestone payment amount received |
|
|
|
|
|
10,000,000 |
|
|
| Milestone payment recognized as revenue |
|
|
|
|
|
$ 4,300,000 |
$ 4,300,000 |
$ 10,000,000 |
| Number of deliverables under license agreement |
6 |
|
|
|
|
|
|
|